These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 21339748)

  • 1. Imatinib is effective for prevention and improvement of fibrotic fasciitis as a manifestation of chronic GVHD.
    Osumi T; Miharu M; Tanaka R; Du W; Takahashi T; Shimada H
    Bone Marrow Transplant; 2012 Jan; 47(1):139-40. PubMed ID: 21339748
    [No Abstract]   [Full Text] [Related]  

  • 2. Successful treatment with imatinib-combined chemotherapy for relapsed Philadelphia-positive acute lymphoblastic leukemia after allogeneic bone marrow transplantation.
    IMAHASHI N; TOKUNAGA M; NISHIWAKI S; YANAGISAWA M; OZAWA Y; MIYAMURA K
    Rinsho Ketsueki; 2009 Nov; 50(11):1612-5. PubMed ID: 20009435
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Imatinib mesylate in combination with chemotherapy in four children with de novo and advanced stage Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Fuster JL; Bermúdez M; Galera A; Llinares ME; Calle D; Ortuño FJ
    Haematologica; 2007 Dec; 92(12):1723-4. PubMed ID: 18056006
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Results of allogeneic bone marrow transplantation for acute leukemia have improved in Europe with time--a report of the acute leukemia working party of the European group for blood and marrow transplantation (EBMT).
    Frassoni F; Labopin M; Gluckman E; Prentice HG; Vernant JP; Zwaan F; Granena A; Gahrton G; De Witte T; Gratwohl A; Reiffers J; Gorin NC
    Bone Marrow Transplant; 1996 Jan; 17(1):13-8. PubMed ID: 8673048
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Imatinib as a potential treatment for sclerodermatous chronic graft-vs-host disease.
    Moreno-Romero JA; Fernández-Avilés F; Carreras E; Rovira M; Martínez C; Mascaró JM
    Arch Dermatol; 2008 Sep; 144(9):1106-9. PubMed ID: 18794453
    [No Abstract]   [Full Text] [Related]  

  • 6. Allogeneic bone marrow transplantation for leukemia with marrow grafts treated by counterflow centrifugation.
    De Witte T; Schattenberg A; Preijers F; Raymakers R; Muus P; Wessels J
    Bone Marrow Transplant; 1993; 12 Suppl 3():S2-6. PubMed ID: 8124252
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A case of sclerodermatous graft-versus-host disease responsive to imatinib therapy.
    Lazar J; Poonawalla T; Teng JM
    Pediatr Dermatol; 2011; 28(2):172-5. PubMed ID: 21504445
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Graft-versus-leukaemia activity associated with CMV-seropositive donor, post-transplant CMV infection, young donor age and chronic graft-versus-host disease in bone marrow allograft recipients. The Nordic Bone Marrow Transplantation Group.
    Jacobsen N; Badsberg JH; Lönnqvist B; Ringdén O; Volin L; Rajantie J; Nikoskelainen J; Keiding N
    Bone Marrow Transplant; 1990 Jun; 5(6):413-8. PubMed ID: 2164434
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Allogeneic cell-mediated immunotherapy using donor lymphocytes for prevention of relapse in patients treated with allogeneic bone marrow transplantation for hematological malignancies.
    Naparstek E; Nagler A; Or R; Kapelushnik J; Slavin S
    Clin Transpl; 1996; ():281-90. PubMed ID: 9286578
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Allogeneic hematopoietic cell transplantation (allogeneic HCT) for treatment of pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia (ALL).
    Burke MJ; Cao Q; Trotz B; Weigel B; Kumar A; Smith A; Verneris MR
    Pediatr Blood Cancer; 2009 Dec; 53(7):1289-94. PubMed ID: 19731318
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interleukin-2 for prevention of graft-versus-host disease after haploidentical marrow transplantation.
    Przepiorka D; Ippoliti C; Koberda J; Chan KW; Khouri IF; Fischer HE; Huh YO; Escudier SM; Seong D; Davis M
    Transplantation; 1994 Oct; 58(7):858-60. PubMed ID: 7940725
    [No Abstract]   [Full Text] [Related]  

  • 12. Allogeneic bone marrow transplantation in children - eight years experience of Paediatric BMT Unit in Poznań.
    Wachowiak J; Boruczkowski D; Malicki J; Kaczmarek-Kanold M; Chobot-Musiałkiewicz U; Radwańska U
    Bone Marrow Transplant; 1998 Dec; 22 Suppl 4():S63-6. PubMed ID: 9916639
    [No Abstract]   [Full Text] [Related]  

  • 13. Administration of imatinib in the first 90 days after allogeneic hematopoietic cell transplantation in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Chen H; Liu KY; Xu LP; Liu DH; Chen YH; Shi HX; Han W; Zhan XH; Wang Y; Zhao T; Huang XJ
    Chin Med J (Engl); 2011 Jan; 124(2):246-52. PubMed ID: 21362375
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acute graft-versus-host disease of the heart.
    Roberts SS; Leeborg N; Loriaux M; Johnson FL; Huang ML; Stenzel P; Thiede C; Godder KT
    Pediatr Blood Cancer; 2006 Oct; 47(5):624-8. PubMed ID: 16206193
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia: a phase II study by the Japan Adult Leukemia Study Group.
    Yanada M; Takeuchi J; Sugiura I; Akiyama H; Usui N; Yagasaki F; Kobayashi T; Ueda Y; Takeuchi M; Miyawaki S; Maruta A; Emi N; Miyazaki Y; Ohtake S; Jinnai I; Matsuo K; Naoe T; Ohno R;
    J Clin Oncol; 2006 Jan; 24(3):460-6. PubMed ID: 16344315
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Re: Imatinib mesylate administration in the first 100 days after stem cell transplantation.
    Anderlini P; Sheth S; Hicks K; Ippoliti C; Giralt S; Champlin RE
    Biol Blood Marrow Transplant; 2004 Dec; 10(12):883-4. PubMed ID: 15570257
    [No Abstract]   [Full Text] [Related]  

  • 17. The value of monitoring minimal residual disease in the patients with donor lymphocyte infusion as intervention of relapsed/refractory acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation.
    Ma X; Wu D; Sun A; Qiu H; Fu Z; Wu X; Chen S; Mohty M
    Am J Hematol; 2010 Feb; 85(2):141-2. PubMed ID: 20029991
    [No Abstract]   [Full Text] [Related]  

  • 18. Bone marrow necrosis associated with the use of imatinib mesylate in a patient with Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Matsue K; Takeuchi M; Koseki M; Uryu H
    Ann Hematol; 2006 Aug; 85(8):542-4. PubMed ID: 16570152
    [No Abstract]   [Full Text] [Related]  

  • 19. Imatinib therapy prior to myeloablative allogeneic stem cell transplantation.
    Zaucha JM; Prejzner W; Giebel S; Gooley TA; Szatkowski D; Kałwak K; Wojnar J; Kruzel T; Balon J; Hołowiecki J; Hellmann A
    Bone Marrow Transplant; 2005 Sep; 36(5):417-24. PubMed ID: 16007105
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intermediate dose of imatinib in combination with chemotherapy followed by allogeneic stem cell transplantation improves early outcome in paediatric Philadelphia chromosome-positive acute lymphoblastic leukaemia (ALL): results of the Spanish Cooperative Group SHOP studies ALL-94, ALL-99 and ALL-2005.
    Rives S; Estella J; Gómez P; López-Duarte M; de Miguel PG; Verdeguer A; Moreno MJ; Vivanco JL; Couselo JM; Fernández-Delgado R; Maldonado M; Tasso M; López-Ibor B; Lendínez F; López-Almaraz R; Uriz J; Melo M; Fernández-Teijeiro A; Rodríguez I; Badell I
    Br J Haematol; 2011 Sep; 154(5):600-11. PubMed ID: 21707583
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.